Relay Therapeutics (RLAY) Other Non-Current Liabilities (2021 - 2024)

Relay Therapeutics (RLAY) has 4 years of Other Non-Current Liabilities data on file, last reported at $11.4 million in Q1 2024.

• On a quarterly basis, Other Non-Current Liabilities fell 63.75% year-over-year to $11.4 million in Q1 2024; TTM through Mar 2024 was $11.4 million, a 63.75% decrease from a year earlier, with the FY2023 full-year figure at $13.2 million, down 59.21% from the prior year.
• Other Non-Current Liabilities for Q1 2024 stood at $11.4 million, down from $13.2 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for RLAY reached as high as $50.5 million in Q3 2021 and fell as low as $11.4 million in Q1 2024.
• Historically, Other Non-Current Liabilities has averaged $35.8 million across 4 years, with a median of $37.6 million in 2022.
• Across the five-year window, Other Non-Current Liabilities retreated 5.37% in 2022 and plunged 63.75% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $50.3 million in 2021, then plunged by 35.58% to $32.4 million in 2022, then tumbled by 59.21% to $13.2 million in 2023, then slipped by 13.87% to $11.4 million in 2024.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $11.4 million in Q1 2024, $13.2 million in Q4 2023, and $28.0 million in Q3 2023.